Skip to content

Implementation of Multiple Micronutrient Supplementation (MMS) for Pregnant Women in Uganda

Implementation of Multiple Micronutrient Supplementation (MMS) for Pregnant Women in Uganda

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06835738
Enrollment
4077
Registered
2025-02-19
Start date
2025-06-18
Completion date
2026-12-31
Last updated
2026-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutrient Deficiency

Brief summary

The objective of this research is to understand how antenatal multiple micronutrient supplements (MMS) can be effectively implemented and scaled within the Uganda national health system context to support improved maternal nutrition and birth outcomes. Formative research has been conducted to design the implementation strategies that will be tested in this second phase of the study. The objectives are to: * Describe the implementation of the MMS intervention (which consists of MMS product, a social behavior change communication (SBCC) strategy, capacity building, MMS supply chain support, monitoring, and evaluation) and explore acceptability, feasibility, fidelity, coverage, and potential for sustainability. * Determine the effect of dispensing MMS in different bottle counts on MMS adherence and ANC attendance among pregnant women. * Determine the cost and budget impact of MMS intervention implementation integrated in the Ugandan ANC service delivery system

Detailed description

Within the context of the existing antenatal care system, investigators will utilize qualitative and quantitative methods to answer the following research questions: 1. What is the acceptability, feasibility, fidelity, coverage, and potential for sustainability of an MMS intervention that includes MMS product, a contextualized social behavior change communication (SBCC) plan, capacity strengthening, and modified recording and reporting). 2. Does the number of MMS pills in a bottle affect/influence adherence to MMS and/or attendance at ANC attend (30 count bottle vs 90 count bottle vs 180-count bottle). 3. What is the cost and budget impact of implementing MMS intervention within the antenatal care (ANC( service delivery system in Uganda. This is a 3-arm quasi-experimental implementation research (IR) study utilizing a mixed methods data collection approach across multiple study populations (e.g., national, regional, and district-level decision makers, healthcare providers, pregnant women, and other community members). The three study arms are: Study Arm #1 (MMS 180-count), Study Arm #2 (MMS 30-count) and Study Arm #3 (MMS 90-count). The IR will be conducted in 8 districts representing the South Central, Acholi, and Karamoja regions of Uganda. Sufficient MMS will be provided to the 8 districts to ensure full implementation of MMS across all government (public) facilities and private not-for-profit (PNFP) facilities within the 8 study districts. In other words, all pregnant women who attend ANC through either a public or PNFP health facility within the 8 study districts will be offered MMS rather than IFA. Each district will be assigned to receive a specific "bottle-count" to be provided to all pregnant women attending ANC in that district. All women will be provided with 180 tablets of MMS delivered in the "bottle-count" option assigned to the district where she is seeking services. The 3 "bottle-count" options are: 1) 1 bottle containing 180 tablets dispensed to the pregnant woman attending the first ANC visit; 2) 2 bottles each containing 90 tablets of MMS dispensed at two different time points during pregnancy; or 3) 6 bottles each containing 30 tablets of MMS dispensed monthly over the course of a woman's pregnancy). All pregnant women who are assigned to a 30 or 90 bottle count will continue with that bottle count throughout the women's life of pregnancy and postpartum period. Each "bottle-count" equates to a study arm. Each of the 3 study regions will have slightly different study arms. The districts/study arms within each region were purposively selected under the formative (phase I) of the study. Because there are 3 districts in both the South-Central Region and the Acholi region, each of the 3 districts will serve as a study arm representing one of the three "bottle-count" options. Because there are only 2 districts in the Karamoja region, there will not be a 90-count study-arm. The study will undertake data collection at approximately 6 facilities per district, representative of the total number of facilities in the districts. Facilities will be purposively selected after being stratified based on the level of the health facility (health center II, health center III, health center IV, or hospital), ownership (government or PNFP), and geographic location.

Interventions

DIETARY_SUPPLEMENTMultiple Micronutrient Supplement (MMS) - dispensed in six 30-count bottles

MMS is a daily supplement provided to pregnant women. It will be delivered to pregnant women through the specified bottle-count protocol as designated by the 3 study arms. ANC providers will be trained to counsel pregnant women on using MMS using a novel job aid/adherence calendar.

DIETARY_SUPPLEMENTMultiple Micronutrient Supplement (MMS) - dispensed in one 180-count bottle

MMS is a daily supplement provided to pregnant women. It will be delivered to pregnant women through the specified bottle-count protocol as designated by the 3 study arms. ANC providers will be trained to counsel pregnant women on using MMS using a novel job aid/adherence calendar.

DIETARY_SUPPLEMENTMultiple Micronutrient Supplement (MMS) - dispensed in two 90-count bottles

MMS is a daily supplement provided to pregnant women. It will be delivered to pregnant women through the specified bottle-count protocol as designated by the 3 study arms. ANC providers will be trained to counsel pregnant women on using MMS using a novel job aid/adherence calendar.

Sponsors

Johns Hopkins Bloomberg School of Public Health
Lead SponsorOTHER
Vitamin Angels
CollaboratorUNKNOWN
UNICEF
CollaboratorOTHER
Child and Family Foundation of Uganda
CollaboratorUNKNOWN
Kirk Humanitarian
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

MMS will be implemented across 8 districts in Uganda within 3 regions of Uganda. Two regions have 3 study districts/arms and one region (Karamoja) has two study districts/arms. Study arms/districts have been purposively selected. * Study Arm 1 (3 districts): Provision of 6 bottles each containing 30 tablets of MMS dispensed monthly over the course of a woman's pregnancy). along with the novel "job aid/adherence calendar" * Study Arm 2 (3 districts): Provision of 1 bottle containing 180 tablets dispensed to the pregnant woman attending the first ANC visit; along with the novel "job aid/adherence calendar" * Study Arm 3 (2 districts): Provision of 2 bottles each containing 90 tablets of MMS dispensed at two different time points during pregnancy along with the novel "job aid/adherence calendar"

Eligibility

Sex/Gender
ALL
Age
0 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

for Pregnant women- Enrolled for follow-up throughout pregnancy (sample 1) * ≤24 weeks of amenorrhea/gestation as verified by health professionals * Attending first ANC visit at government or PNFP health facilities. * Accepted to take MMS at first ANC visit

Exclusion criteria

for Pregnant women- Enrolled for follow-up throughout pregnancy (sample 1) * Pregnant women with pre-existing hematological conditions such as sickle cell anemia, thalassemia, hemochromatosis. * Pregnant women planning to relocate outside the study district during the study period. Inclusion Criteria for Pregnant women / Women that have recently delivered (single contact) (sample 2) * Currently pregnant woman or a woman who is not more than 8 weeks postpartum. * Received MMS at an ANC visit at least 3 months ago or more. * Attended at least any 2 monthly ANC visits. * Attending/attended ANC at government or private-not-for-profit health facility.

Design outcomes

Primary

MeasureTime frameDescription
MMS Adherence (amount) as assessed by number of MMS tablets consumed3-month post-enrolment, 6-month post-enrolment visit, 6-week postpartum visitThe number of MMS tablets (from a total possible 180 tablets) a pregnant woman consumes (sample 1).
MMS Adherence (frequency) as assessed by the frequency of tablets consumed3-month post-enrolment, 6-month post-enrolment visit, 6-week postpartum visitThe frequency of which MMS tablets are consumed by a pregnant woman. (sample group 1)
ANC Adherence as assessed by the number of ANC visits throughout pregnancy3-month post-enrolment, 6-month post-enrolment visit, 6-week postpartum visitThe number of ANC visits (from a total possible of 8 visits) a pregnant woman makes throughout her pregnancy (sample 1)

Secondary

MeasureTime frameDescription
Proportion of pregnant women who indicate MMS Acceptability3-month post-enrolment visit, 6-month post-enrolment visit, 6-week postpartum visitThe proportion of pregnant women (sample group 1 and 2) who agree with domain-specific statements which reflect different aspects of MMS acceptability (MMS packaging, MMS physical properties, MMS side effects, and MMS counseling using The Theoretical Framework of Acceptability uses a 5-point Likert scale where 5 is "strongly agree" and 1 is "strongly disagree". Score range 5-35, a higher score reflects higher acceptability.
MMS Acceptability among Health Providers assessed by focus group discussions6 months, 12 monthsHealthcare provider acceptability of MMS across multiple domains (e.g., feasibility of delivering counseling and packaging, time burden) (sample group 5). Measured via focus group discussions at two time points during the study (middle and end).
Fidelity of providing MMS among Health Providers as assessed by focus group discussions3-months, 6-months, 9-months, and 12-monthsAdministration of an observation checklist (sample group 3) and a Healthcare Provider Survey (sample 5) at 4 time points during the study

Countries

Uganda

Contacts

CONTACTHarriet Babikako, PhD
babikako@yahoo.com256-0704-584-089
PRINCIPAL_INVESTIGATORMonica Fox, MHS

Johns Hopkins University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 2, 2026